Biobots was founded in 2014 to make it easy to design and engineer biology. Bioprinters on the market were expensive, inaccessible, and difficult to use. Biobots created its beta device to tackle these problems and enjoyed rapid adoption but the academic community. Three years later the company – now Allevi – has grown to serve hundreds of labs in all corners of the world.
The company formerly known as Biobots has grown to be a leader in the field of 3D biofabrication with a community of users who are literally changing the field of medicine. From Yu Shrike Zhang at MIT who published the first ever thrombosis-on a chip, to Julio and Andrea at Wake Forest University printing tumor models.
Biobot’s new name, Allevi, was inspired by its community of users who work every day to make living solutions for humanity’s most important problems – to cure disease, to alleviate suffering, to build with life. When your work has life-changing implications for people all over the world, it’s an amazing responsibility. That ingenuity. That importance. That’s Allevi.
Allevi is also launching a new software that standardizes experimental workflow, ensures repeatability, and puts the control in the user’s hands. It has a few exciting key features: An integrated slicer allows users to focus on the parameters that matter to create a successful print while allowing us to do the heavy lifting of preparing the design file. The projects feature allows users to create and save digital printing protocols making it easy to replicate and alter experiments week after week.
Well categorization means that users can now use a multi-well dish and vary the parameters in each well, allowing you to test several variables at once to find that optimum print. Whether you’re trying to achieve certain rheological standards, build a complex geometry or optimize for high cell viability- you can control it all.
Most importantly, Allevi’s new software makes printing easy and contributes to the company’s mission to make 3D biofabrication accessible to all.